Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3822
|
pubmed:dateCreated |
1969-9-19
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0036-8075
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
29
|
pubmed:volume |
159
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1492
|
pubmed:dateRevised |
2009-3-9
|
pubmed:meshHeading |
pubmed-meshheading:5732495-Amphetamine,
pubmed-meshheading:5732495-Catecholamines,
pubmed-meshheading:5732495-Euphoria,
pubmed-meshheading:5732495-Hallucinations,
pubmed-meshheading:5732495-Hallucinogens,
pubmed-meshheading:5732495-Humans,
pubmed-meshheading:5732495-Placebos,
pubmed-meshheading:5732495-Psychopharmacology
|
pubmed:year |
1968
|
pubmed:articleTitle |
2,5-Dimethoxy-4-methylamphetamine: new hallucinogenic drug.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|